Rinri Therapeutics
Develops regenerative cell therapies for people with sensorineural hearing loss
Highlights
- New on EvolcAdded 2026-10-31
About Rinri Therapeutics
Rinri Therapeutics develops regenerative cell therapies intended to replace damaged inner-ear sensory cells and treat sensorineural hearing loss. Its first product, Rincell-1, is expected to enter clinical trials.
The company was founded in 2018 and is based in Sheffield, UK. Its work is based on research by founder Professor Marcelo Rivolta at the University of Sheffield, and it is backed by venture investors and non-dilutive funding.
Product: A portfolio of regenerative cell therapy candidates for sensorineural hearing loss, including Rincell-1.
Jobs at Rinri Therapeutics
No open positions listed right now.
Leadership
- Marcelo Rivolta · Founder and Chief Scientific OfficerSource: company website
- Simon Chandler · Chief Executive OfficerSource: company website
- Terri Gaskell · Chief Technology OfficerSource: company website
More biotech & pharma companies
RoukenBio
Preclinical immunology research and assay services for biotechnology and drug development companiesRemote-friendlySalary transparentRxbiologics
Antibody discovery services for biologics drug discovery programmes, built on a proprietary human antibody libraryNew on EvolcScancell
Clinical-stage immunotherapy developer for difficult-to-treat cancers, using Immunobody and Moditope platformsNew on EvolcScripta Therapeutics
Drug discovery platform using transcription factor mapping and AI models to find neurodegenerative disease therapiesYoung companyNew on EvolcSisaf
RNA drug-delivery platform licensed to pharma partners, with a research reagent for labs plannedNew on EvolcSitala Bio
Develops medicines targeting harmful inflammation for patients with neurodegenerative and inflammatory diseasesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Complianz
- Google Analytics 4
- LiteSpeed
- WordPress
- jQuery